Alitair Announces Notice of Patent Allowance for Safer Formulation of Benzonatate

Published: Sep 27, 2012

MORRISTOWN, N.J.--(BUSINESS WIRE)--Alitair Pharmaceuticals, Inc., today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its ion exchange resin formulation of benzonatate. The patent includes specific claims for reducing or eliminating the choking hazard associated with conventional liquid formulations of benzonatate.

Back to news